

-continued

ctgaagatgt tgcaacttat tactgtcaaa agtataacag	280
tgccctctctc acctteggcc aagggacacg actggagatt	320
aaacgaactg tggctgcacc atctgtcttc atcttcccgc	360
catctgatga gcagttgaaa tctggaactg cctctgttgt	400
gtgctgctg aataacttct atcccagaga ggccaaagta	440
cagtggaagg tggataacgc cctccaatcg ggtaactccc	480
aggagagtgt cacagagcag gacagcaagg acagcaccta	520
cagcctcagc agcaccctga cgtgagcaa agcagactac	560
gagaaacaca aactctaagc ctgcgaagtc acccatcagg	600
gcttgagctc gcccgtcaca aagagcttca acaggggaga	640
gtgttaa	647

What is claimed is:

1. A composition comprising a combination of F1 and V antibodies, wherein said F1 antibodies comprise an F1 antibody having the amino acid sequence of SEQ ID NO: 3, SEQ ID NO:5, or an antibody fragment that retains the complementarity determining regions (CDRs) of SEQ ID NO: 3, SEQ ID NO:5.

2. The composition of claim 1 wherein said V antibodies comprise an antibody having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:11, or antibody fragment thereof that retains the complementarity determining regions (CDRs) of SEQ ID NO: 9, SEQ ID NO:11.

3. The composition of claim 1 wherein said V antibodies comprise an antibody having amino acid sequence of SEQ ID NO: 13, SEQ ID NO:15, or an antibody fragment thereof that retains the complementarity determining regions (CDRs) of SEQ ID NO: 13, SEQ ID NO:15.

4. The composition of claim 3 wherein said V antibodies comprise a second V antibody having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:11, or antibody fragment thereof that retains the complementarity determining regions (CDRs) of SEQ ID NO: 9, SEQ ID NO:11.

5. The composition of claim 1 wherein said composition is a pharmaceutical composition.

6. The composition of claim 2 wherein said composition is a pharmaceutical composition.

7. The composition of claim 3 wherein said composition is a pharmaceutical composition.

8. The composition of claim 4 wherein said composition is a pharmaceutical composition.

9. A method for detecting, in a sample, *Y. pestis*, said method comprising:

- (i) incubating the sample with an effective amount of the composition of claim 1, under conditions which allow the formation of an antibody-*Y. pestis* complex; and
- (ii) detecting the antibody-*Y. pestis* complex wherein the presence or absence of the complex indicates the presence or absence or said *Y. pestis* in the sample.

10. A method for detecting *Y. pestis* according to claim 9 wherein said sample is a biological sample.

11. A method for treating *Y. pestis* infection comprising administering to a patient in need of said treatment an amount of the composition of claim 5 sufficient to effect said treatment.

12. A method for treating *Y. pestis* infection comprising administering to a patient in need of said treatment an amount of the composition of claim 6 sufficient to effect said treatment.

13. A method for treating *Y. pestis* infection comprising administering to a patient in need of said treatment an amount of the composition of claim 7 sufficient to effect said treatment.

14. A method for treating *Y. pestis* infection comprising administering to a patient in need of said treatment an amount of the composition of claim 8 sufficient to effect said treatment.

15. A method for detecting, in a sample, F1 from *Y. pestis*, said method comprising:

- (i) incubating the sample with an effective amount of the composition of claim 1, under conditions which allow the formation of an antibody-F1 complex; and
- (ii) detecting the antibody-F1 complex wherein the presence or absence of the complex indicates the presence or absence or said F1 from *Y. pestis* in the sample.

16. A method for detecting, in a sample, V antigen from *Y. pestis*, said method comprising:

- (i) incubating the sample with an effective amount of a composition comprising V antibodies having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:11, or antibody fragment thereof that retains the complementarity determining regions (CDRs) of SEQ ID NO: 9, SEQ ID NO:11, and/or V antibodies having amino acid sequence of SEQ ID NO: 13, SEQ ID NO:15, or an antibody fragment thereof that retains the complementarity determining regions (CDRs) of SEQ ID NO: 13, SEQ ID NO:15, under conditions which allow the formation of an antibody-V antigen complex; and
- (ii) detecting the antibody-V antigen complex wherein the presence or absence of the complex indicates the presence or absence or said V antigen from *Y. pestis* in the sample.

* * * * *